이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

일상적인 임상 실습에서 건선성 관절염 환자의 Guselkumab 및 Interleukin-17(IL-17) 억제제 요법에 대한 연구 (PsABIOnd)

2026년 11월 2일 업데이트: Janssen Pharmaceutica N.V., Belgium

일상적인 임상 실습에서 건선성 관절염 환자의 Guselkumab(Tremfya) 및 IL-17 억제제 요법의 평가; 전향적 관찰 코호트 연구

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.

연구 유형

관찰

등록 (실제)

1314

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 10676
        • Evangelismos General Hospital of Athens
      • Athens, 그리스, 11527
        • Laiko General Hospital of Athens
      • Athens, 그리스, 11521
        • Athens Navy Hospital
      • Athens, 그리스, 11527
        • General Hospital 'Gennimatas'
      • Athens, 그리스, 11527
        • Hippokration General Hospital of Athens, B' Internal Medicine Clinic,
      • Ioannina, 그리스, 45560
        • University Hospital of Ioannina
      • Pátrai, 그리스, 263 32
        • 'Agios Andreas' General Hospital of Patras
      • Pátrai, 그리스, 26500
        • University General Hospital of Rio Patras
      • Thessaloniki, 그리스, 546 42
        • Ippokrateio Hospital
      • Amsterdam, 네덜란드, 1105 AZ
        • Academisch Medisch Centrum Universiteit van Amsterdam
      • Enschede, 네덜란드, 7500 KA
        • Medisch Spectrum Twente
      • Groningen, 네덜란드, 9700 RB
        • Universitair Medisch Centrum Groningen
      • Helmond, 네덜란드, 5707 HA
        • Elkerliek Ziekenhuis
      • Kaohsiung City, 대만, 81362
        • Kaohsiung Veterans General Hospital
      • Kaohsiung City, 대만, 83301
        • Chang Gung Medical Foundation
      • Taichung, 대만
        • Taichung Veterans General Hospital
      • Cheonan-si, 대한민국, 31151
        • Soonchunhyang University Cheonan Hospital
      • Seongnam, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center
      • Amberg, 독일, 92224
        • Praxis für Rheumatologie
      • Bayreuth, 독일, 95444
        • Rheuma-Praxis Bayreuth
      • Berlin, 독일, 12161
        • Rheumatologische Schwerpunktpraxis
      • Berlin, 독일, 13055
        • Rheumatologische Schwerpunktpraxis 1
      • Cologne, 독일, 51149
        • Krankenhaus Porz am Rhein
      • Düsseldorf, 독일, 40225
        • Universitatsklinikum Dusseldorf
      • Erfurt, 독일, 99096
        • Service Rheuma Erfurt
      • Frankfurt, 독일, 60590
        • Universitatsklinikum Frankfurt
      • Halle, 독일, 6128
        • Rheumapraxis Dr. Liebhaber
      • Hamburg, 독일, 22767
        • Rheumatologie im Struenseehaus
      • Hamburg, 독일, 22415
        • Praxis fur Klinische Studien und Praxis fur Orthopadie
      • Herne, 독일, 44649
        • Rheumazentrum Ruhrgebiet
      • Leipzig, 독일, 04109
        • Rheumatologische Praxis 1
      • Magdeburg, 독일, 39104
        • Rheumatologische Praxis
      • München, 독일, 81541
        • Praxiszentrum St. Bonifatius
      • Neubrandenburg, 독일, 17033
        • Praxis Thilo Klopsch
      • Püttlingen, 독일, 66346
        • Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie
      • Ratingen, 독일, 40878
        • Rheumazentrum Ratingen
      • Templin, 독일, 17268
        • Rheumatologisch-immunologische Arztpraxis
      • Vogelsang-Gommern, 독일, 39245
        • Immunologisches Zentrum Vogelsang-Gommern GmbH
      • Kemerovo, 러시아 제국, G4 0SF
        • SBEU HPE Kemerovo State Medical Academy
      • Moscow, 러시아 제국, 121552
        • Bakoulev Scientific Center For Cardiovascular Surgery Rams
      • Moscow, 러시아 제국, 190068
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Tomsk, 러시아 제국, 634045
        • City Hospital #3
      • Mérida, 멕시코, 97070
        • Medical Care & Research SA de CV
      • México, 멕시코, 07760
        • Consultorio de Reumatologia
      • Zapopan, 멕시코, 45116
        • Hospital Puerta de Hierro
      • Bruges, 벨기에, 8000
        • AZ Sint-Jan
      • Brussels, 벨기에, 1070
        • Hopital Erasme
      • Genk, 벨기에, 3600
        • Reumaclinic Genk-Hasselt
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Liège, 벨기에, 4000
        • CHU de Liège - Domaine Universitaire du Sart Tilman
      • Gothenburg, 스웨덴, 41345
        • Sahlgrenska Universitetssjukhuset
      • Malmö, 스웨덴, 20502
        • Universitetssjukhuset i Lund
      • Stockholm, 스웨덴, 113 65
        • Akademiskt Specialistcentrum centrum för reumatologi
      • Uppsala, 스웨덴, 75185
        • Akademiska Sjukhuset
      • Örebro, 스웨덴, 70185
        • Universitetssjukhuset Orebro
      • Fribourg, 스위스, 1708
        • HFR Fribourg - Hôpital Cantonal
      • A Coruña, 스페인, 15006
        • Hosp Univ A Coruna
      • Algeciras / Cadiz, 스페인, 11207
        • Hosp. Punta de Europa
      • Barcelona, 스페인, 08036
        • Hosp Clinic de Barcelona
      • Barcelona, 스페인, 8035
        • Hosp Univ Vall D Hebron
      • Bilbao, 스페인, 48013
        • Hosp. Univ. de Basurto
      • Córdoba, 스페인, 14004
        • Hosp Reina Sofia
      • Granada, 스페인, 18016
        • Complejo hospitalario de Granada
      • Madrid, 스페인, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28905
        • Hosp. Univ. de Getafe
      • Oviedo, 스페인, 33011
        • Hosp. Univ. Central de Asturias
      • Santiago de Compostela, 스페인, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, 스페인, 41013
        • Hosp. Virgen Del Rocio
      • Buenos Aires, 아르헨티나, C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, 아르헨티나, C1221ADC
        • Hospital J. M. Ramos Mejía
      • Buenos Aires, 아르헨티나, C1015ABO
        • OMI
      • Córdoba, 아르헨티나, 5000
        • Hospital Cordoba
      • San Fernando, 아르헨티나, B1646
        • MR Medicina Reumatologica
      • Aberdeen, 영국, AB25 2ZB
        • NHS Grampian - Aberdeen Royal Infirmary (ARI)
      • Abergavenny, 영국, NP7 7EG
        • Nevill Hall Hospital
      • Airdrie, 영국, ML6 0JS
        • University Hospital Monklands
      • Barnet, 영국, EN5 3DJ
        • Royal Free London NHS Foundation Trust Barnet Hospital
      • Bath, 영국, BA1 3NG
        • Wolfson Centre Royal United Hospitals
      • Glasgow, 영국, 650029
        • Glasgow Royal Infirmary
      • Hull, 영국, HU3 2JZ
        • Hull Royal Infirmary
      • Leeds, 영국, LS7 4SA
        • Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital
      • Manchester, 영국, M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle upon Tyne, 영국, NE7 7DN
        • The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
      • Portsmouth, 영국, PO6 3LY
        • Queen Alexandra Hospital
      • Salford, 영국, M6 8HD
        • Shirley Caldwell
      • Southampton, 영국, SO16 6YD
        • Southampton General Hospital
      • Staffordshire, 영국, ST6 7AG
        • Haywood Hospital
      • Stamford, 영국, PE9 1UA
        • Stamford and Rutland hospital
      • Wishaw, 영국, ML2 0DP
        • Wishaw General
      • Graz, 오스트리아, 8036
        • LKH-Univ. Klinikum Graz
      • Linz, 오스트리아, 4021
        • Kepler Universitatsklinikum GmbH
      • Vienna, 오스트리아, 1090
        • Medizinische Universitaet Wien
      • Vienna, 오스트리아, A-1100
        • Evang. Krankenhaus Gemein. Betriebgesm. Mbh
      • Bari, 이탈리아, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
      • Campobasso, 이탈리아, 86100
        • Ospedale Regionale Cardarelli-Università degli Studi del Mol
      • Catanzaro, 이탈리아, 88100
        • Universita della Magna grecia
      • Florence, 이탈리아, 50141
        • AOU Careggi
      • Naples, 이탈리아, 80131
        • Azienda Ospedaliera Universitaria Federico II
      • Naples, 이탈리아, 80131
        • Seconda Univesità degli Studi di Napoli, AOU
      • Palermo, 이탈리아, 90127
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Pisa, 이탈리아, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Potenza, 이탈리아, 85100
        • Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale
      • Rome, 이탈리아, 20123
        • Universita Cattolica del Sacro Cuore
      • Rozzano, 이탈리아, 20156
        • Istituto Clinico Humanitas
      • Torino, 이탈리아, 10126
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino
      • Udine, 이탈리아, 33100
        • Azienda Ospedaliero Universitaria S.Maria Della Misericordia
      • Verona, 이탈리아, 37067
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Hyōgo, 일본, 6751392
        • Kita-harima Medical Center
      • Meguro-ku, 일본, 153-8515
        • Toho University Medical Center, Ohashi Hospital
      • Osaka, 일본, 550 0006
        • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
      • Osaka, 일본, 545 8586
        • Osaka Metropolitan University Hospital
      • Sapporo, 일본, 060-8648
        • Hokkaido University Hospital
      • Tokyo, 일본, 181 8611
        • Kyorin University Hospital
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 1J9
        • Artus Health Centre
    • Manitoba
      • Winnipeg, Manitoba, 캐나다, R3A 1M3
        • Manitoba Clinic
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, 캐나다, A1C 5B8
        • St. Claire's Mercy Hospital - Rheumatology Research
    • Nova Scotia
      • Coxheath, Nova Scotia, 캐나다, B1L 1B3
        • Dr. Juris Lazovskis Incorporated
    • Ontario
      • Dundas, Ontario, 캐나다, L9H 1B7
        • Private Practice - Dr. Pauline Boulos
      • Markham, Ontario, 캐나다, L3R 2C7
        • Markham Rheumatology Hub
      • Mississauga, Ontario, 캐나다, L5A 3V8
        • Brandusa Florica Medicine Professional Corporation
      • Orillia, Ontario, 캐나다, L3V 1T5
        • The Waterside Clinic
      • Ottawa, Ontario, 캐나다, K1H 7W9
        • The Ottawa Hospital Research Institute
      • Windsor, Ontario, 캐나다, N8X 1T3
        • Dr Sabeen Anwar Medicine Professional Corporation
    • Quebec
      • Montreal, Quebec, 캐나다, H1T 2M4
        • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
      • Québec, Quebec, 캐나다, G1V 4K5
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Rimouski, Quebec, 캐나다, G5L 5T1
        • Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
      • Trois-Rivières, Quebec, 캐나다, G9A 3X2
        • Centre de Recherche Musculo Squelettique
    • Saskatchewan
      • Saskatoon, Saskatchewan, 캐나다, S7K 0H6
        • Community Rheumatology Care
      • Saskatoon, Saskatchewan, 캐나다, S7K 0H6
        • Rheumatology Associates of Saskatoon
      • Bogotá, 콜롬비아
        • BIOMAB
      • Bucaramanga, 콜롬비아
        • Servimed S A S
      • Medellín, 콜롬비아, 50012
        • Clinisalud del Sur
      • Medellín, 콜롬비아, 50025
        • Clinica Vascular las Americas
      • Montería, 콜롬비아, 230002
        • Funcentra
      • Bobigny, 프랑스, 93000
        • Hôpital Avicenne
      • Cholet, 프랑스, 49300
        • Centre Hospitalier de Cholet
      • Clermont-Ferrand, 프랑스, 63003
        • Hôpital Gabriel Montpied
      • Créteil, 프랑스, 94000
        • Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor
      • Lille, 프랑스, 59037
        • CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur
      • Lyon, 프랑스, 69008
        • Centre Orthopedique Santy
      • Lyon, 프랑스, 69300
        • Clinique de l'Infirmerie Protestante de Lyon
      • Nice, 프랑스, 6006
        • Hôpital Saint Roch
      • Orléans, 프랑스, 45032
        • CHR Orléans - Nouvel Hôpital Orléans La Source
      • Paris, 프랑스, 75018
        • Hôpital Bichat
      • Paris, 프랑스, 75010
        • Hôpital Lariboisière - Centre Viggo Petersen
      • Paris, 프랑스, 75012
        • Hopital Saint-Antoine
      • Paris, 프랑스, 75651
        • Hopital Pitie Salpetriere
      • Strasbourg, 프랑스, 67098
        • CHRU Hôpital de Hautepierre
      • Toulouse, 프랑스, 31059
        • Hopital Purpan
      • Échirolles, 프랑스, 38130
        • CHU Grenoble
      • Adelaide, 호주, 5011
        • The Queen Elizabeth Hospital
      • Footscray, 호주
        • Footscray Hospital, Western Health
      • St Leonards, 호주, 2065
        • Royal North Shore Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

해당 없음

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.

설명

Inclusion Criteria:

Main study:

  • Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
  • Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
  • Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations

Substudy:

  • Must sign the substudy ICF allowing data collection in accordance with local requirements
  • Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
  • Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities

Exclusion Criteria:

Main study:

  • Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
  • Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)

Substudy:

  • Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
  • Unwilling or unable to comply with substudy assessments

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Cohort 1: Guselkumab

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.

다른 이름들:
  • 트렘피아
Cohort 2: Interleukin-17 inhibitor (IL-17i)

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
기간: Up to 39 months

The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
기간: Up to 39 months

The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
기간: Baseline up to 39 months

Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet.

Baseline up to 39 months
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
기간: Baseline up to 39 months

The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm).

Baseline up to 39 months
Change from Baseline in Assessment of Dactylitis
기간: Baseline up to 39 months

The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented.

Baseline up to 39 months
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
기간: Baseline up to 39 months

The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right).

Baseline up to 39 months
Change from Baseline in Nail Involvement
기간: Baseline up to 39 months

Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes.

Baseline up to 39 months
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
기간: Baseline up to 39 months

The BSA score indicates the surface area of the participant's body effected by psoriasis.

Baseline up to 39 months
Change from Baseline in C-reactive Protein (CRP)
기간: Baseline up to 39 months

Change from baseline in CRP will be reported.

Baseline up to 39 months
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
기간: Baseline up to 39 months

Change from Baseline in MDA/VLDA will be reported.

Baseline up to 39 months
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
기간: Baseline up to 39 months

DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Baseline up to 39 months
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
기간: Up to 39 months

Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Up to 39 months
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
기간: Up to 39 months

Start and stop dates of all treatments and the sequence of treatment lines will be reported.

Up to 39 months
Percentage of Participants with Adverse Events (AEs)
기간: Up to 39 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 39 months
BSA PSO Skin Involvement
기간: Up to 39 months

The BSA score indicates the surface area of the participant's body affected by psoriasis.

Up to 39 months
Rheumatic Disease Comorbidity Index
기간: Up to 39 months

Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported.

Up to 39 months
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
기간: Baseline up to 6 months

FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain.

Baseline up to 6 months
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
기간: Baseline up to 39 months

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems.

Baseline up to 39 months
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
기간: Baseline up to 39 months

The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.

Baseline up to 39 months
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
기간: Baseline up to 39 months

PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline up to 39 months
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
기간: Baseline up to 39 months

The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week.

Baseline up to 39 months
Change from Baseline in Pain VAS Score
기간: Baseline up to 39 months

The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm).

Baseline up to 39 months
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
기간: Baseline up to 39 months

BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity.

Baseline up to 39 months
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
기간: Baseline up to 39 months

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value.

Baseline up to 39 months
Change from Baseline in Dermatology Life Quality Index (DLQI)
기간: Baseline up to 39 months

The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant.

Baseline up to 39 months
Change from Baseline in Patient Acceptable Symptom State (PASS)
기간: Baseline up to 39 months

The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being.

Baseline up to 39 months
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
기간: Baseline up to 39 months

The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

Baseline up to 39 months
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
기간: Baseline up to 39 months

TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication.

Baseline up to 39 months
Number of Participants Switching or Stopping Treatment
기간: Up to 39 months

Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported.

Up to 39 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 8월 25일

기본 완료 (추정된)

2027년 8월 1일

연구 완료 (추정된)

2027년 8월 2일

연구 등록 날짜

최초 제출

2021년 8월 31일

QC 기준을 충족하는 최초 제출

2021년 9월 17일

처음 게시됨 (실제)

2021년 9월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR108938
  • CNTO1959PSA4001 (기타 식별자: Janssen Research & Development, LLC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다